Zontivity

(Vorapaxar)

ApprovedSmall molecule

Akero Therapeutics

Zontivity is one of 97 small molecule programs targeting Myocardial Infarction. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Myocardial InfarctionCompleted

Diabetes MellitusCompleted

Myocardial InfarctionApproved

Completed

Diabetes MellitusApproved

Completed

Competition

Competitive Landscape

113 competitors in Diabetes Mellitus

#DrugCompanyPhaseTrials

Onglyza

AstraZeneca

Approved

1 2

Prograf

VVeloxis Pharmaceuticals

Approved

1 3

Viagra

VViatris Specialty LLC

Approved

1 4

Adrenaline

SSamson Clinical Operations Pty Ltd

Approved

—5

Flovent

PParatek Pharmaceuticals Inc

Approved

—6

Proair HFA

GGlaxo Dba Glaxosmithkline

Approved

—7

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 8

Zontivity

Akero Therapeutics

Approved

1 9

Retatrutide

Eli Lilly

Phase 3

1 10

Zofran

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Coronary Syndrome2 trials

Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT00527943·12,944 enrolled

Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00684203·120 enrolled

Atherosclerosis2 trials

Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00526474·26,449 enrolled

Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00617123·258 enrolled

Extremity1 trial

Vorapaxar and Lower Extremity Bypass Grafts

Withdrawn·VVanderbilt University·Phase 4·NCT02975583

Endotoxemia1 trial

Vorapaxar in the Human Endotoxemia Model

Completed·MMedical University of Vienna·Phase 4·NCT02875028·16 enrolled

Coagulation1 trial

Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints

Completed·KKirby Institute·Phase 1/2·NCT02394730·65 enrolled

4 more indications

Cerebral Infarction1 trial

Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00684515·90 enrolled

Diabetes Mellitus1 trial

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

Completed·UUniversity of Florida·Phase 4·NCT02548650·66 enrolled

Myocardial Infarction1 trial

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

Completed·UUniversity of Florida·Phase 4·NCT02545933·130 enrolled

Unspecified1 trial

Vorapaxar on Thrombin Generation and Coagulability

Completed·IInova Health Care Services·Phase 4·NCT03207451·81 enrolled

Regulatory

FDA Approval Timeline[4]

May 8, 2014

ZONTIVITY

NDA NDA204886

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Vorapaxar. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vorapaxar compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vorapaxar. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA204886). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Zontivity. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Akero Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Akero Therapeutics

Patent Landscape[5]

Patent Cliff

Dec 23, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7304078Dec 23, 2027

Zontivity

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Coronary Syndrome2 trials

Atherosclerosis2 trials

Extremity1 trial

Endotoxemia1 trial

Coagulation1 trial

Cerebral Infarction1 trial

Diabetes Mellitus1 trial

Myocardial Infarction1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News